Eluciderm, Inc. Wins WHS Wound Shark 2024 Innovation Award
June 22 2024 - 2:56PM
Business Wire
- Eluciderm, Inc. wins prestigious international wound healing
award.
- Eluciderm’s lead wound healing drug, ELU42, mimics the
capabilities of superhealer mice.
- ELU42 is nearing the clinical trial stage.
Eluciderm, Inc. announced today that it won the Wound Healing
Society’s Wound Shark 2024 Innovation Award at the 2024
International Symposium for Advanced Wound Care (SAWC 2024). This
honor goes to the most innovative company of the year in the wound
healing space. The judges awarded the trophy to Eluciderm as
recognition for the anticipated market impact of ELU42, a
first-of-its-kind, topically administered, small-molecule drug
designed to accelerate and enhance the healing of all wound types,
including diabetic foot ulcers, third-degree burns, and traumatic
open soft tissue wounds, all with little to no scarring.
Eluciderm’s Chief Executive Officer, Dr. Daniel Holsworth, PhD,
said, “It is very gratifying to be recognized as an up-and-coming
leader in the field of regenerative medicine. We believe the
paradigm shift we bring to wound healing with our novel technology
and pipeline of small-molecule therapeutics will make the
difference between simply managing patients’ wounds and truly
healing them.”
At the core of Eluciderm’s innovation is ELU42, a small-molecule
Wnt signaling pathway inhibitor. Where decades of legacy research
in the field of wound healing focused on stimulating the Wnt
pathway, Eluciderm took the opposite approach. Inspiration for this
new way of looking at the fundamentals of wound healing is grounded
in the seminal academic research done with superhealer mice by Dr.
Sarika Saraswati, PhD, Eluciderm’s Vice President of Molecular
Biology. These mice are capable of healing themselves quickly after
injury, and with no scarring. Dr. Saraswati said, “Our 10 years of
laboratory studies mimicking the functionality of the Wnt pathway
of superhealer mice revealed the intriguing possibility of
regenerating healthy tissue by modulating the Wnt pathway. It is
both humbling and exciting to think that our basic biological
research has inspired the development of a medicine that could help
people.”
The potential market impact of a drug capable of fully closing
all wound types with little to no scarring is massive because no
such treatment currently exists. Dr. John Delgado, MD, FAAFM,
Eluciderm’s Chief Medical Officer: “As a physician with a
background in functional medicine, I can tell you that a
pharmaceutical that can close all open wounds and regenerate
healthy tissue is the Holy Grail of wound healing.” In fact, the
need for wound healing drugs is so dire that in 2022 the FDA issued
a request for innovation in the development of small molecule drugs
to treat chronic wounds. Dr. Delgado noted the high bar Eluciderm
has set for itself: “It is our hope that what Eluciderm has created
with ELU42, whether it’s used alone as a topical spray or in
conjunction with existing bandages and dressings on the market,
will be a game changer. We believe everyone can be a
superhealer.”
In conclusion, Dr. Holsworth stated: “The entire Eluciderm Team
would like to thank WHS for this prestigious award. It provides a
great burst of momentum as we shift gears in the next few months
from research and testing to advancing our novel series of
therapeutics into the clinic, and, ultimately, to market.”
About Eluciderm, Inc.
Founded in 2018, Eluciderm, Inc. is a late-stage, regenerative
medicine-focused pharmaceutical company that is developing small
molecules to address wound healing and dermatological diseases. For
more information about Eluciderm, visit www.eluciderm.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240622508614/en/
Dr. Daniel Holsworth, CEO.
dholsworth@eluciderminc.com; 734 255 0366